Immunogenicity and safety of a DTAP-IPV//PRP∼T vaccine (Pentaxim™) booster during the second year of life in thai children primed with an acellular pertussis combined vaccine

Southeast Asian Journal of Tropical Medicine and Public Health

Volumn 40, Issue 2, 2009, Pages 282-294

  Thisyakorn, Usa ^a   Pancharoen, Chitsanu ^a   Chuenkitmongkol, Sunate ^b   Ortiz, Esteban ^c  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

^b Sanofi Pasteur   (Thailand)

^c SANOFI PASTEUR   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 63149190788     PISSN: 01251562     EISSN: 26975718     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. AAP Pediatrics Committee on Infectious Diseases. Recommended immunization schedules for children and adolescents-United States, 2008. Pediatrics 2008; 121: 219-20.
2. Cameron C, Pebody R. Introduction of pneumococcal conjugate vaccine to the UK childhood immunization programme and changes to the meningitis C and Hib schedules. Euro Surveill 2006;11. [Cited 2008 Sep 10]. Available from: URL: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=2913
3. Capeding RM, Cadorna-Carlos J, BookMontellano M, Ortiz E. Immunogenicity and safety of a DTaP-IPV//PRP∼T combination vaccine at 6, 10, 14 weeks of age (EPI schedule) and concomitant hepatitis B vaccination at birth, 6, 14 or 6, 10, 14 weeks of age. Bull WHO 2008; 86: 443-51.
4. Carlsson RM, Claesson BA, Fagerlund UE, Knutsson N, Laudin C. Antibody persistence in five-year old children who received a pentavalent combination vaccine in infancy. Pediatr Infect Dis J 2002; 21: 1535-41.
5. Carlsson RM, Claesson BA, Selstam U, et al. Safety and immunogenicity of a combined diphtheria, tetanus, acellular pertussis- inactivated polio vaccine- Haemophilus influenzae type b vaccine administered at 2-4-6-13 or 3-5-12 months of age. Pediatr Infect Dis J 1998; 17: 1026-33.
6. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997; 16 (suppl4): S90-6.
7. Cherry JD, Brunell PhA, Golden GS, Karzon DT. Report of the Task Force on Pertussis and Pertussis Immunization. Pediatrics 1988; 81: 933-84.
8. Cruces RP, Donoso FA, Camacho AJ, Llorente HM. Invasive infections caused by Haemophilus influenzae type b after the institution of the conjugated vaccine on the expanded program on immunization in Chile. Rev Chilena Infectol 2006; 23: 50-4.
9. Decker MD, Edwards KM, Steinhoff MC, et al. Comparison of 13 acellular pertussis vaccines: adverse reactions. Pediatrics 1995; 96: 557-66.
10. th ed. Philadelphia: Saunders, 2008; 21: 467-517.
11. Edwards KM, Meade BD, Decker MD, et al. Comparison of 13 acellular pertussis vaccines: overview and serologic response. Pediatrics 1995; 96: 548-57.
12. Eglund JA, Decker MD, Edwards KM, Pichichero ME, Steinhoff MC, Anderson EL. Acellular and whole-cell pertussis vaccines as booster doses: a multicenter study. Pediatrics 1994; 93: 37-43.
13. Fitzgerald M, Canny M, O'Flanagan D. Vaccination catch-up campaign in response to recent increase in Hib infection in Ireland. Euro Surveill 2005, 10 (39): E050929.2. [Cited 2008 Sep 10]. Available from: URL: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId-2800
14. Grimprel E, Bégué P, Anjak I, Njamkepo E, François P, Guiso N.Long-term human serum antibody responses after immunization with whole-cell pertussis vaccine in France. Clin Diagn Lab Immunol 1996; 3: 93-7.
15. Guiso N, Njamkepo E, Vié le Sage F, et al. Longterm humoral and cell-mediated immunity after acellular pertussis vaccination compares favourably with whole-cell vaccines 6 years after booster vaccination in the second year of life. Vaccine 2007; 25: 1390-7.
16. Gustafsson L, Hessel L, Storsaeter J, Olin P. Longterm follow-up of Swedish children vaccinated with acellular pertussis vaccines at 3, 5, and 12 months of age indicates the need for a booster dose at 5 to 7 years of age. Pediatrics 2006; 118: 978-84.
17. Hessel L, Mast CH, Teyssou R. Effectiveness of the 2-component acellular pertussis combination vaccine 5 years experience of routine practice in Sweden [Abstract 18.023]. Int J Infect Dis 2004; 8 (suppll): S75.
18. nd ed. New York, NY: Marcel Dekker, 1997: 387-16.
19. Johnson NG, Ruggeberg JU, Balfour GF, et al. Haemophilus influenzae type b reemergence after combination immunization. Emerg Infect Dis 2006; 12: 937-41.
20. Kanra G, Selier T, Yurdakök K, et al. Immunogencity study of a combined diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis vaccine used to reconstitute a freeze-dried Haemophilus influenzae type b vaccine (DTacP-IPV//PRP-T) administered simultaneously with a hepatitis B vaccine at two, three and four months of life. Vaccine 2000; 18: 947-54.
21. Lagos R, Kotloff, KL Hoffenbach A, et al. Clinical acceptability and immunogenicity of a pentavalent parenteral combination vaccine containing diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis and Haemophilus influenzae type b conjugate antigens in two-, four- and six month-old Chilean infants. Pediatr Infect Dis J 1998; 17: 294-304.
22. Langue J, Matisse N, Pacoret P, Undreiner F, Boisnard F, Soubeyrand B. Persistence of antibodies at 5-6 years of age for children who had received a primary series vaccination with a pentavalent whole-cell pertussis vaccine and a first booster with a pentavalent acellular pertussis vaccine: immunogenicity and tolerance of second booster with a tetravalent acellular vaccine at 5-6 years of age. Vaccine 2004; 22: 1406-14.
23. Mallet E, Fabre P, Pines E, et al. Immunogenicity and safety of a new liquid hexavalent combined vaccine compared with separate administration of reference licensed vaccines in infants. Pediatr Infect Dis J 2000; 19: 1119-27.
24. Mallet E, Matisse N, Mathieu N, et al. Antibody persistence against diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b (Hib) in 5-6-year-old children after primary vaccination and first booster with a pentavalent combined acellular pertussis vaccine: immunogenicity and tolerance of a tetravalent combined acellular pertussis vaccine given as a second booster. Vaccine 2004; 22: 1415-22.
25. MMWR. Pertussis vaccination: use of acellular pertussis vaccines among infants and young children recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recom Rep 1997; 46 (RR-7):1-25. [Cited 2008 Sep 10]. Available from: URL: http://www.cdc.gov/mmwr/PDF/rr/rr4607. pdf
26. MOPH Thailand, Bureau of General Communicable Diseases, Department of Disease Control. Vaccination schedule. [Cited 2008 Sep 23]. Available from: URL: http://thaigcd.ddc.moph.go.th/Vac-Tables.html
27. Olin P, Hallander HO. Marked decline in pertussis followed reintroduction of pertussis vaccination in Sweden. Euro Surveil 1999; 4: 128-29. [Cited 2008 Sep 10]. Available from: URL: http://www.eurosurveillance.org/ViewArticle. aspx?ArticleId=84
28. th ed. Part 3.2006. Ottawa: Recommended Immunization Public Health Agency of Canada. [Cited 2008 Sep 10]. Available from: URL: http://www.phac-aspc.gc.ca/publicat/ciggci/p03-01- eng.php
29. Pichichero ME, Deloria MA, Rennels MB, et al. A safety and immunogenicity comparison of 12 acellular pertussis vaccines and one whole-cell pertussis vaccine given as a fourth dose in 15- to 20-month-old children. Pediatrics 1997; 100: 772-88.
30. Ryan EJ, Nilsson L, Kjellman N, Gothefors L, Mills KH. Booster immunization of children with an acellular pertussis vaccine enhances Th2 cytokine production and serum IgE responses against pertussis toxin but not against common allergens. Clin Exp Immunol 2000; 12: 193-200.
31. Simondon F, Preziosi MP, Yam A, et al. A randomized double-blind trial comparing a two-component acellular to a whole-cell pertussis vaccine in Senegal. Vaccine 1997;15: 1606-12.
32. SMI. Swedish Institute for Infectious Disease Control. Pertussis surveillance in Sweden with enhanced follow-up of cohorts immunized with acellular pertussis vaccines 2006 Appendix 2 SP-MSD. [Cited 2008 Sep 10]. Available from: URL: http://www.smittskyddsinstitutet.se/upload/PDF-filer/seven- year-report-app-2-SP-MSD.pdf
33. Therre H, Baron S. Pertussis immunisation in Europe - the situation in late 1999. Euro Surveill 2000; 5: 6-10. [Cited 2008 Sep 10]. Available from: URL: http://www.eurosurveillance.org/em/v05n01/v05n01.pdf
34. WHO. The Children's Vaccine Initiative and the Global Programme for Vaccines and Immunization. Recommendations from the Special Advisory Group of Experts. Part 1. Wkly Epidemiol Rec 1997; 72: 237-43.
35. WHO. Pertussis vaccines. WHO position paper. Weekly Epidemiol Rec 2005;80: 29-40. [Cited: 2008 Sep 10], Avilable from: URL: http://whqlibdoc.who. int/wer/WHO-WER-2005/80-29-40(no4).pdf
36. WHO. United Nations prequalified vaccines (WHO list of vaccines for purchase by UN agencies as of September 2008a). [Cited 2008 Sep 10]. Available from: URL: http://www.who.int/immunization-standards/vaccine-quality/pq- suppliers/en/index.html
37. WHO. Vaccine preventable diseases monitoring system 2008b Global summary: Country profile selection center. [Cited 2008 Sep 10]. Available from: URL: http://www.who.int/vaccines/globalsummary/immunization/countryprofileresult.cfm? C=%27tha%27